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The Use of Bronchoscopy During the
Coronavirus Disease 2019 Pandemic
CHEST/AABIP Guideline and Expert Panel Report
Momen M. Wahidi, MD; Samira Shojaee, MD, MPH; Carla R. Lamb, MD; David Ost, MD, MPH; Fabien Maldonado, MD;
George Eapen, MD; Daniel A. Caroff, MD, MPH; Michael P. Stevens, MD, MPH; Daniel R. Ouellette, MD; Craig Lilly, MD;
Donna D. Gardner, DrPH, RRT, FCCP; Kristen Glisinski, MD; Kelly Pennington, MD; and Raed Alalawi, MD
BACKGROUND: The coronavirus disease 2019 (COVID-19) has swept the globe and is causing
significant morbidity and mortality. Given that the virus is transmitted via droplets, open
airway procedures such as bronchoscopy pose a significant risk to health-care workers
(HCWs). The goal of this guideline was to examine the current evidence on the role of
bronchoscopy during the COVID-19 pandemic and the optimal protection of patients and
HCWs.
STUDY DESIGN ANDMETHODS: A group of approved panelists developed key clinical questions
by using the Population, Intervention, Comparator, and Outcome (PICO) format that
addressed specific topics on bronchoscopy related to COVID-19 infection and transmission.
MEDLINE (via PubMed) was systematically searched for relevant literature and references
were screened for inclusion. Validated evaluation tools were used to assess the quality of
studies and to grade the level of evidence to support each recommendation. When evidence
did not exist, suggestions were developed based on consensus using the modified Delphi
process.
RESULTS: The systematic review and critical analysis of the literature based on six PICO
questions resulted in six statements: one evidence-based graded recommendation and 5
ungraded consensus-based statements.
INTERPRETATION: The evidence on the role of bronchoscopy during the COVID-19 pandemic
is sparse. To maximize protection of patients and HCWs, bronchoscopy should be used
sparingly in the evaluation and management of patients with suspected or confirmed
COVID-19 infections. In an area where community transmission of COVID-19 infection is
present, bronchoscopy should be deferred for nonurgent indications, and if necessary to
perform, HCWs should wear personal protective equipment while performing the procedure
even on asymptomatic patients. CHEST 2020; -(-):---
KEY WORDS: bronchoscopy; COVID-19; personal protective equipment
ABBREVIATIONS: AABIP = American Association for Bronchology
and Interventional Pulmonology; AGP = aerosol generating procedure;
CDC = Centers for Disease Control and Prevention; CHEST =
American College of Chest Physicians; COVID-19 = coronavirus dis-
ease 2019; GRADE = Grading of Recommendations, Assessment,
Development and Evaluations; HCW = health-care worker; PAPR =
powered air purifying respirator; PICO = Population, Intervention,
Comparator, and Outcome; PPE = personal protective equipment;
rRT-PCR = real-time reverse transcription-polymerase chain reaction;
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
AFFILIATIONS: From the Department of Medicine (Drs Wahidi and
Glisinski), Division of Pulmonary, Allergy and Critical Care, Duke
University School of Medicine, Durham, NC; the Department of
Medicine (Drs Shojaee and Stevens), Divisions of Pulmonary and
Critical Care and Infectious Disease, Virginia Commonwealth Uni-
versity, Richmond, VA; the Department of Medicine
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Summary of Recommendations
1. When patients with suspected or confirmed
COVID-19 infection are undergoing bronchoscopy,
we suggest that health care workers in the procedure
and recovery rooms use either an N-95 respirator or a
powered air purifying respirator (Ungraded
Consensus-Based Statement).
Remarks:
 In addition, health care workers should wear personal
protection equipment including face shield, gown and
gloves.
 N-95 respirators should be discarded after
bronchoscopy.
2. In patients suspected of having COVID-19
infection, we suggest that a nasopharyngeal specimen
be obtained first. In the setting of severe or
progressive disease requiring intubation, if additional
specimen is needed to establish a diagnosis of
COVID-19 or other diagnosis that will change clinical
management, lower respiratory specimens from
endotracheal aspirate or bronchoscopy with BAL can
be performed (Ungraded Consensus-Based Statement).
Remarks: More research is needed to further compare
diagnostic sensitivity for COVID-19 infection utilizing
other less invasive lower respiratory specimen
collection techniques such as blinded bronchial
sampling, blinded protected brush and non-
bronchoscopic mini-BAL.
3. When asymptomatic patients present for
bronchoscopy in an area where community spread of
COVID-19 is present, we suggest that health care
workers in the procedure room wear N-95 respirators
or powered air-purifying respirators as opposed to
surgical masks (Ungraded Consensus-Based
Statement).
Remarks: In addition, health care workers should wear
personal protection equipment including face shield,
gown and gloves.
4. Prior to performing bronchoscopy in asymptomatic
patients in an area where community transmission of
COVID-19 infection is present, we suggest testing for
COVID-19 infection (Ungraded Consensus-Based
Statement).
Remarks:
 This strategy is contingent on the availability of
testing in the local setting.
 In all patients with negative results, we suggest that
the procedure is performed using personal protection
equipment including face shield, gown, gloves and
N-95 respirators or powered air purifying respirators
(PAPR).
 When test results are positive prior to bronchoscopy,
we suggest postponing all non-emergent
bronchoscopies.
 In patients who require emergent bronchoscopy who
have positive SARS-CoV-2 test results, we suggest
using personal protection equipment including face
shield, gown, gloves and N-95 respirators or powered
air purifying respirators (PAPR) in pre, intra, and
post bronchoscopy settings as would be with every
SARS-Cov-2 positive patient.
5. When bronchoscopy is indicated to diagnose, stage,
or characterize a known or suspected lung cancer in
an area where community transmission of COVID-19
is present, we suggest that bronchoscopy be
performed in a timely and safe manner (Grade 2C).
Remarks:
 Strategies to perform bronchoscopy in a timely manner
should be developed locally, taking into account local
resource availability including availability of personal pro-
tective equipment, availability of COVID-19 testing and
availabilityofdownstreamresourcesrequiredfortreatment
(eg, surgery requires ICU beds and ventilators).
(Drs Lamb and Caroff), Divisions of Pulmonary and Critical Care and
Infectious Disease, Lahey Hospital and Medical Center, Burlington,
MA; the Department of Medicine (Drs Ost and Eapen), Division of
Pulmonary and Critical Care, University of Texas MD Anderson
Cancer Center, Houston, TX; the Department of Medicine (Dr Mal-
donado), Division of Allergy, Pulmonary and Critical Care, Vanderbilt
University, Nashville, TN; the Department of Medicine (Dr Ouellette),
Division of Pulmonary and Critical Care, Henry Ford Health System,
Detroit, MI; the Department of Medicine (Dr Lilly), Division of Pul-
monary and Critical Care, University of Massachusetts, Worcester,
MA; the Department of Respiratory Care (Dr Gardner), Texas State
University, Round Rock, TX; the Department of Medicine (Dr Pen-
nington), Division of Pulmonary and Critical Care, Mayo Clinic,
Rochester, MN; and the Department of Medicine (Dr Alalawi), Divi-
sion of Pulmonary and Critical Care, University of Arizona, Phoenix,
AZ.
DISCLAIMER: CHEST Guidelines are intended for general information
only, are not medical advice, and do not replace professional medical
care and physician advice, which should always be sought for any
medical condition. The complete disclaimer for this guideline can be
accessed at: http://www.chestnet.org/Guidelines-and-Resources.
CORRESPONDENCE TO: Momen M. Wahidi, MD, Division of Pul-
monary, Allergy & Critical Care Medicine, Duke University School of
Medicine, Box 102356, Durham, NC 27710; e-mail: momen.wahidi@
duke.edu
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 Regional availability of diagnostic and therapeutic
interventions for cancer patients should be consid-
ered. In particularly resource-depleted hospitals,
COVID-19 negative cancer patients should be
referred to other centers, preserving resources for
COVID-19 patients and facilitating safe, timely, and
effective care for the cancer patient as well.
 Although efforts should be made to provide timely
care, these should be balanced by the need to attend to
other dimensions of quality, including safety, effec-
tiveness, and consistency with patient values and
preferences.
6. In patients with confirmed COVID-19 infection
who recover and need a routine bronchoscopy, we
suggest that the timing of the procedure be
customized based on the indication for the procedure,
the severity of the COVID-19 infection and time from
symptom resolution (Ungraded Consensus-Based
Statement).
Remarks: The exact time to perform bronchoscopy is
still unknown. It would be reasonable to wait at least
30 days from resolution of symptoms with negative
SARS-CoV-2 RNA tests from at least two consecutive
nasopharyngeal swab specimens collected $24 hours
apart. Further research is needed to better understand
optimal timing of bronchoscopy performance relative to
symptom resolution.
Background
The coronavirus disease 2019 (COVID-19) pandemic
has manifested primarily as a severe lower respiratory
tract illness with significant associated morbidity and
mortality throughout the globe.1 Transmission is
generally via respiratory droplets, but airborne
transmission may be possible with aerosol generating
procedures (AGPs) such as bronchoscopy.2 Therefore,
bronchoscopy and other AGPs put health-care workers
(HCWs) at particularly high risk of exposure and
infection. Under these trying circumstances, the medical
community has three overarching imperatives. The first
is to ensure the protection and welfare of all patients,
irrespective of their COVID-19 status. The second is to
preserve the health-care workforce to sustainably meet
the first responsibility, and finally, the third is to
promote the health of the community at large.
Although specific data on the risk of infection with
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) during bronchoscopy are not available, the US
Centers for Disease Control and Prevention (CDC)
recommends performing these AGPs in an airborne
infection isolation room with an N95 respirator or
higher-level respirator, eye protection, gloves, and
gown.3 These considerations and the often
overwhelming demand on available human and material
resources during a pandemic necessitates thoughtful and
deliberate balancing of the tradeoffs that may be
required to optimally fulfil the primary responsibilities
of the health-care system.
In an effort to provide interim guidance to health-care
practitioners, various specialty societies have issued
statements germane to their particular specialties. The
American Association for Bronchology and
Interventional Pulmonology (AABIP)4 recently issued a
statement on the use of bronchoscopy in COVID-19.
Most of these statements have relied primarily on the
available CDC guidance and the consensus opinions of
single specialty experts. This report provides an in-
depth, multidimensional, and multidisciplinary review
of the available scientific evidence and puts forward
suggestions for key clinical scenarios that many
practitioners are likely to face. In such a kinetic milieu,
these can be expected to evolve based on an expanding
evidence base, the public health burden of disease, and
the availability of trained personnel or medical
infrastructure. These suggestions are therefore best
envisioned as a decision-making framework that
continually strives for optimality among possibly
competing mandates.
Methods
The primary aim of this collaborative effort between the American
College of Chest Physicians (CHEST) and AABIP was to create a list
of clinically relevant recommendations and suggestions for HCWs
who perform bronchoscopy during the COVID-19 pandemic. We
chose to base recommendations on the assumption that resources
are abundant. These recommendations can then be adapted by local
decision-makers based on resource availability. Using the assumption
that resources (for prevention, diagnosis, and treatment) are
plentiful, we aimed to answer some of the most common and
important questions related to bronchoscopy during the COVID-19
pandemic.
Panelist and Content Expert Selection
CHEST and AABIP participated in the selection of panelists. Two
cochairs were assigned to lead this endeavor (M. M. W. appointed
by AABIP and R. A. appointed by CHEST). Cochairs in
conjunction with CHEST and AABIP leadership nominated two
methodologists (S. S. and D. O.) and core panelists (G. E., C. R.
L., F. M., D. O., and S. S.) based on their clinical expertise in
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bronchoscopy and interventional pulmonology. Advisory panel
members consisted of infectious disease experts (M. P. S. and D.
A. C.), critical care medicine experts (D. R. O. and C. L.), an
interventional pulmonology trainee (K. G.), a pulmonary and
critical care trainee (K. P.), and a respiratory therapist (D. D. G.)
nominated and selected by both organizations. All panel members
received individual education regarding the process and schedule,
followed by conflict of interest disclosure and evaluation by cochairs.
Guideline creation schedule was developed by cochairs. Given the time-
sensitive nature of the topic amid on-going COVID-19 pandemic, the
schedule spanned over a period of 3 weeks and included 10
conference calls including topic and question development, literature
search, literature evaluation using Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) methodology,
discussion, modified Delphi surveys, and statement development.
Question Development and Systematic Search
Cochairs and core panelists discussed and developed the primary
questions in the Population, Intervention, Comparator, and Outcome
(PICO) format during the first conference call. Six PICO questions
were developed and assigned to each core panelist for literature
review (Table 1).
To identify relevant evidence, the panel members conducted a
comprehensive search using MEDLINE via PubMed followed by
manual search related to each a priori developed PICO question.
Search strategy, evidence table, and details of search results depicted
in a Preferred Reporting Items for Systematic Reviews and
Meta-Analyses diagram for each PICO question are available in
e-Appendix 1.
Studies were excluded if they were not available in English or if they
were single case reports. Expert reviews, opinions, and statements
were not included, but their references were reviewed to search for
additional evidence.
Study Selection and Evidence Assessment
Each panel member screened their respective search results to exclude
duplicates, followed by title and abstract screen, excluding literature
based on a priori established exclusion criteria. All remaining text
was reviewed and direct and indirect evidence was selected and
presented in evidence tables for final review and core panel
discussion. With the exception of one single-center retrospective
observational study related to PICO question 2,5 and 13 studies
related to PICO question 5,6-18 no other direct evidence was
identified. Evidence was graded by the methodology team using the
standard GRADE quality assessment tool categorized as high,
moderate, low, or very low.19,20 With exception of PICO question 5,
none of the available direct and indirect literature provided sufficient
evidence for the development of recommendations. Expert opinion
instead was sought to answer these PICO questions in form of
suggestions in place of recommendations. Suggestions were
developed based on the use of a modified Delphi process.
Method for Achieving Consensus
Search results were shared and discussed among members during a
conference call with 100% participation. Evidence graded by the
methodology team and summary of evidence and suggestions written
by respective panel members for each PICO question were disclosed
to all panel members including the advisory panel. During the
conference call, suggestions were reviewed and rewritten in real time
per adjustment and suggestions from the panel. This was followed
by another conference call with 100% participation, soliciting
additional comments and input from the advisory panel. All panel
members participated in the development of suggestions to be
incorporated in the initial round of the modified Delphi survey.T
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The modified Delphi technique is a widely accepted method for the
development of consensus among experts.21-23 To achieve consensus, a
priori decision was made to conduct up to three rounds of
anonymous voting or until consensus was achieved (defined a priori
as consensus agreement at $ 80% with a minimal response rate of
80%) for each PICO question, whichever came first. To maintain
complete transparency and limit bias from interaction among
members, additional discussions outside of the scheduled meetings
before voting were discouraged. The survey incorporated the
suggestions made by all panelists and was developed and reviewed by
chairs and methodologists and sent to all panel members by a
CHEST-designated project coordinator. The project coordinator tallied
and reported the results of the survey to the group, and all votes were
anonymous. The results of the survey were discussed with all panel
members including the advisory panel on the same day during a
group discussion. There was 100% survey participation from the
members and consensus was achieved on four PICO questions. After
discussion and revision of statements, a second round of surveys was
distributed, including three questions (two questions did not achieve
consensus and one question required rewriting based on panel
recommendation). There was 100% survey participation and
agreement on all three PICO questions from the second survey.
Results
1. When patients with suspected or confirmed
COVID-19 infection are undergoing bronchoscopy,
we suggest that health care workers in the procedure
and recovery rooms use either an N-95 respirator or a
powered air purifying respirator (Ungraded
Consensus-Based Statement).
Remarks:
 In addition, health care workers should wear personal
protection equipment including face shield, gown and
gloves.
 N-95 respirators should be discarded after
bronchoscopy.
COVID-19 is caused by SARS-CoV-2 and currently
understood to be transmitted from person-to-person
via droplets, contact, and fomites, largely based on
prior epidemiologic data from the previous coronavirus
outbreaks.24 Accordingly, the World Health
Organization and the CDC have made
recommendations for HCWs and individuals to
maintain a 1-m (3-ft) or 2-m (6-ft) distance,
respectively, from patients suspected of being
infected.25,26 Routinely performed AGPs such as
bronchoscopy have however been associated with
infection of HCWs despite droplet and contact
precautions, prompting the CDC and many scientific
societies to recommend airborne precautions in these
circumstances.4,25,27 Although data specific to SARS-
CoV-2 are lacking, a systematic review reported ORs
for transmission of SARS-CoV-2 to HCWs of 6.6
(95% CI, 2.3-18.9), 4.2 (95% CI, 1.5-11.5), and 1.9
(95% CI, 0.2-14.2) for endotracheal intubation,
tracheostomy, and bronchoscopy, respectively;
however, the association with bronchoscopy did not
reach statistical significance.28 One study demonstrated
that SARS-CoV-2 could remain aerosolized for up to
3 h in experimental conditions.29 The CDC currently
recommends the use of either powered air purifying
respirators (PAPRs) with contact precautions or N95
respirators based enhanced respiratory and contact
precautions (including eye protection) as comparable
strategies for protection of HCWs during AGPs such as
bronchoscopy.30
Our systematic review did not identify any study directly
comparing these two interventions, either in the context
of SARS-CoV-2 or other pathogens associated with a
risk of aerosolization during bronchoscopy. A
theoretical benefit of PAPRs over N95 respirators is a
higher assigned protection factor, as defined by the
minimum factor by which exposure is reduced, which
ranges from 25 to 1,000 for PAPRs vs 10 for N95
respirators (higher number representing higher filtration
efficiency).31 Accordingly, during the 2009 influenza
pandemic, the CDC, Occupational Safety and Health
Administration, and Institute of Medicine suggested the
use of PAPRs over other precautions during AGPs.32 In
addition, PAPRs do not require prior fit testing (which
even when performed appropriately does not guarantee
consistent face seal), are more comfortable, are reusable
(a potential benefit in times of scarce resources), and do
not require an additional face shield.32 N95 respirators,
conversely, do not afford protection unless a tight seal is
maintained throughout the procedure and may be
uncomfortable because of resistance of airflow and CO2
rebreathing.33,34 The reusability of PAPRs may however
carry significant risks of contamination if donning and
doffing and decontamination procedures are not strictly
followed. Errors in don and doff procedures may be
more common with PAPRs, exposing HCWs and
patients to possible contamination.35 Other potential
downsides of PAPRs include availability, upfront
investment, storage issues, maintenance (high-efficiency
particulate filter and battery), training issues, and
possibly movement limitations which may interfere with
highly technical procedures.32 Although the higher
assigned protection factor of PAPRs provides increased
protections, these practical considerations do not allow
firm conclusions favoring one intervention over the
other.
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One major characteristic of the COVID-19 pandemic
has been the shortage of personal protective equipment
(PPE) for HCWs, specifically regarding face masks and
N95 respirators. The CDC suggested that the extended
N95 respirator use (same N95 respirator used for
consecutive patients) and reuse (N95 respirator donned
and doffed multiple times) for 8 h (continuous or
intermittent) may be acceptable under specific
conditions provided (1) the respirator is not damaged,
hard to breathe through, or contaminated; (2) the
respirator is discarded after close interaction with
patients under contact precautions or after AGPs; and
(3) appropriate handwashing is performed before and
after touching or adjusting the respirator. We agree with
these recommendations and suggest that N95 respirator
be discarded after bronchoscopy.
2. In patients suspected of having COVID-19 infection,
we suggest that a nasopharyngeal specimen be obtained
first. In the setting of severe or progressive disease
requiring intubation, if additional specimen is needed
to establish a diagnosis of COVID-19 or other
diagnoses that will change clinical management, lower
respiratory specimens from endotracheal aspirate or
bronchoscopy with BAL can be performed (Ungraded
Consensus-Based Statement).
Remarks: More research is needed to further compare
diagnostic sensitivity for COVID-19 infection utilizing
other less invasive lower respiratory specimen collection
techniques such as blinded bronchial sampling, blinded
protected brush and non-bronchoscopic mini-BAL.
The optimal test to detect COVID-19 infection centers
around a balance of the availability of the test, timeliness
of result, diagnostic yield, and invasiveness of sampling,
while minimizing the risk of disease transmission to
HCWs. To generate guidance for best practice in the
diagnostic assessment for COVID-19 infection, it is
reasonable to use available data from prior
recommendations on similar infections such as Middle
East respiratory syndrome coronavirus and influenza A
(H1N1) coupled with known assessment of the risk of
AGPs.28,36 Data was published on 1,070 specimens from
205 patients with COVID-19 infections, described as
having a spectrum of severity of symptoms from mild
fever, dry cough, and fatigue to more severe respiratory
symptoms, who underwent a variety of specimen
collections from different sites; however, the severity of
illness was not distinguished relative to the sites sampled
and the number of some sampled sites was small. The
specimen sites were described and confirmed with
real-time reverse transcription-polymerase chain
reaction (rRT-PCR) testing for COVID-19 infections,
identifying positive rates in 14 of 15 (93%) of BAL
specimens, 72 of 104 (72%) of sputum samples, five of
eight (63%) of nasal swabs, six of 13 (46%) of
bronchoscopic brush samples, 126 of 398 (32%) of
pharyngeal swabs, 44 of 153 (29%) of feces samples,
three of 307 (1%) of blood samples, and zero of 72 (0%)
of urine samples.5 Given sample size, the true sensitivity
for each site is not fully known in this setting.5 The
World Health Organization37 online guidelines for
COVID-19 suggest that endotracheal aspirate or
bronchoscopy with BAL be considered if a single upper
respiratory specimen is negative and there is clinical
concern because of severe or progressive disease.
When reviewing the literature for comparisons of
various techniques for respiratory specimens and
distinguishing upper and lower respiratory tract
specimens, there are limited data assessing diagnostic
yield in bacterial pathogens and none specifically for
viruses or SAR-CoV-2. The literature on ventilator-
associated pneumonia described multiple sampling
methods to detect pathogens including endotracheal
aspirate, blinded bronchial sampling, blinded
protected brush, nonbronchoscopic mini-BAL, and
bronchoscopic BAL.38-40 When these particular
sampling modalities were reviewed and compared
with endotracheal aspirates in that setting, the data
did not suggest superiority of a specific technique
performed nonbronchoscopically and cited high
variability and inconsistency in standardization of
technique.
Beyond actual specimen collection, it will be important
to follow safety procedures for transport and processing
of the specimens in the laboratory setting. Lower
respiratory specimen testing and handling for COVID-
19 is different than upper respiratory specimen testing
and may require expert laboratory facilities and
therefore longer turnaround times.41
We determined that because bronchoscopy is an AGP,
minimizing risk of transmission of infection to HCWs
should be considered and less invasive modalities of
establishing the diagnosis of COVID-19 should be used
first. The role of lower respiratory specimens via
endotracheal aspirate or bronchoscopy can be
considered in the setting of severe progressive disease
after negative upper respiratory specimens or when
considering an alternative diagnosis which may lead to a
change in clinical management.
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3. When asymptomatic patients present for
bronchoscopy in an area where community spread of
COVID-19 is present, we suggest that health care
workers in the procedure room wear N-95 respirators
or powered air-purifying respirators (PAPR) as
opposed to surgical masks (Ungraded Consensus-Based
Statement).
Remarks: In addition, health care workers should wear
personal protection equipment including face shield,
gown and gloves.
In a major pandemic like the one we are experiencing
with COVID-19, a guiding principle of health-care
delivery is full protection of HCWs to preserve the
workforce able to care for sick patients. The SARS-CoV-
2 virus presents a major challenge because people can
carry the virus but remain asymptomatic, and therefore,
can transmit the infection to fellow humans and HCWs
while seemingly appearing healthy.42,43
A mathematical model, that simulated the
spatiotemporal dynamics of COVID-19 infections
among 375 Chinese cities prior to travel restrictions,
showed that undocumented infections were the infection
source for 79% of documented infections.44 A small
study of 24 asymptomatic infected patients from China
found that the median communicable period, defined as
the interval from the first day of positive nucleic acid
tests to the first day of continuous negative tests, was
9.5 days (up to 21 days).45
Another study evaluated 468 COVID-19 transmission
events that were reported in mainland China outside of
Hubei Province and estimated presymptomatic
transmission of the infection at 12.6%.46
Asymptomatic communication of infection becomes a
major concern when community transmission is
confirmed in a geographic area. This is particularly
concerning to HCWs performing open airway
procedure such as bronchoscopy in such a community.
We sought to determine whether HCWs should don
N95 respirators or surgical masks during bronchoscopy
performed on asymptomatic patients and found only
one study related to COVID-19 infections. Wang et al47
retrospectively evaluated the infection rate among
HCWs in a Chinese hospital in two different groups: the
first group was comprised of staff at high-risk units
(respiratory, infectious disease, and ICU wards) who
wore N95 respirators and cleaned hands frequently,
whereas the second group included staff in other
less-risky wards who did not wear surgical masks and
washed their hands occasionally. Despite a higher
exposure to patients with COVID-19 infection, none of
the 278 staff (56 doctors and 222 nurses) in the N95
respirator group became infected, whereas 10 of 213
staff (77 doctors and 136 nurses) from the no-mask
group were confirmed as infected. The study did not
speculate as to whether the protection of HCWs in the
N95 respirator group was solely because of wearing the
mask or aided by the frequent handwashing strategy.
A meta-analysis conducted in 2020 showed that the use
of N95 respirators compared with surgical masks was
not associated with a lower rate of transmission of
influenza.48 Another recent systematic review and meta-
analysis found low certainty evidence suggesting that
surgical masks and N95 respirators offer similar
protection against viral respiratory infection during
nonaerosol generating care. However, the study
recommended use of N95 respirators for high-risk AGPs
such as bronchoscopy.49
The panel reached consensus favoring wearing N95
respirators vs surgical masks based on the weak evidence
that originated from China supporting the superior
protection of N95 respirators over surgical masks
against COVID-19 infections and the serious
consequences of exposing HCWs to asymptomatic
patients carrying the COVID-19 infection.
4. Prior to performing bronchoscopy in asymptomatic
patients in an area where community transmission of
COVID-19 infection is present, we suggest testing for
COVID-19 infection (Ungraded Consensus-Based
Statement).
Remarks:
 This strategy is contingent on the availability of
testing in the local setting.
 In all patient with negative results, we suggest that the
procedure be performed using personal protection
equipment including face shield, gown, gloves and
N-95 respirators or powered air purifying respirators
(PAPR).
 When test results are positive prior to bronchoscopy,
we suggest postponing all non-emergent
bronchoscopies.
 In patients who require emergent bronchoscopy with
either a known positive SARS-CoV-2 test results or
unknown infection status due to inability to test
emergently, we suggest using personal protection
equipment including face shield, gown, gloves and
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N-95 respirators or powered air purifying respirators
(PAPR) in pre, intra, and post bronchoscopy settings
as would be with every SARS-CoV-2 positive patient.
Our comprehensive literature search showed no direct
evidence comparing COVID-19 testing vs no testing
prior to bronchoscopy in any population, including
asymptomatic patients. Examination of the existing
indirect evidence shows that effect estimates of
asymptomatic disease proportion in the population and
infection transmission rates are limited by population
heterogeneity, small sample size, selection bias because
most asymptomatic patients may never seek medical
attention to undergo testing, and lack of adjustment for
other covariates; all of this results in significant
imprecision in effect estimates.
The diagnosis of SARS-CoV-2 is based on viral RNA
detection using rRT-PCR tests. Multiple molecular
assays are available and new assays are being developed
around the world.50,51 Debates about the efficiency,
sensitivity, and availability of the tests have been
ongoing, both within and outside the United States. The
Food and Drug Administration has granted emergency
use authorization to > 20 commercial COVID-19
diagnostic tests and assays. Different rRT-PCR tests’
sensitivities are reported in the literature ranging from
59% to 97%.52,53
Interpretation of negative test results becomes even
harder in an asymptomatic patient without suspicion of
disease. Numerous potential preanalytical and analytical
deficiencies exist in the diagnosis of COVID-19 infection
ranging from inadequate procedures for specimen
collection and handling, sample contamination,
inadequately validated assays, and misinterpretation of
expression profiles as noted by Lippi et al.41 Ongoing
refinement of molecular targets and validation of rRT-
PCR assays are underway.
Although direct evidence regarding the utility of
COVID-19 testing prior to bronchoscopy does not exist,
review of the existing literature supports the presence of
patients with asymptomatic COVID-19 in the
community. Some but not all asymptomatic patients
may be identified through testing. However, a
proportion of these asymptomatic patients may have
false-negative results. During a pandemic crisis and
when dealing with highly contagious infections, there
are numerous factors that play a role in every response.
The decision to use a test relies on more than just test
sensitivity and specificity. Some of the other factors that
play a significant role are the magnitude of harm that
comes from lack of infection detection, potential
actionable items once infection is identified, and overall
loss and cost to the public at large, should an infected
individual go unrecognized. In the case of COVID-19
infection, a major consideration is the prevalence of
asymptomatic disease. When asymptomatic disease is
rare, the need for extensive workup and testing may be
unnecessary, and harm may outweigh the benefit.
If a patient with asymptomatic COVID-19 who is in
need of urgent bronchoscopy is tested positive,
postponing the bronchoscopy may protect HCWs who
would have come in contact with the patient. This in
turn can reduce the chance of infection transmission to
vulnerable patients by asymptomatic HCWs during the
incubation period. Additionally, patients who would
come in contact with a patient with asymptomatic
COVID-19 during the postbronchoscopy recovery
period are spared. Inevitably, some asymptomatic
patients may be missed on a false-negative test and
undergo bronchoscopy. However, given all elective and
semielective bronchoscopies are avoided, and some
asymptomatic patients are detected on testing, the
number of infected individuals who would not be
detected can be significantly diminished, decreasing the
frequency of harm. This highlights the importance of
testing as a tool for risk reduction and not risk
elimination.
Assuming an ideal scenario with abundant availability of
resources, performing tests prior to every bronchoscopy
in an asymptomatic patient in the era of COVID-19
pandemic mitigates risks to HCWs and patients. We
fully realize that test availability may be limited even for
symptomatic patients and therefore this strategy may
not be feasible in highly endemic areas. An equally
important approach in these settings is to limit the
number of bronchoscopy procedures performed and
postpone most of them unless absolutely necessary.
Table 2 provides general guidance to bronchoscopists on
procedure urgency.
Acknowledging the possibility of false negative results,
necessary respiratory protection and appropriate PPE
should be used to prevent transmission of disease during
bronchoscopy, on asymptomatic patients who were not
detected on testing.
5. When bronchoscopy is indicated to diagnose, stage,
or characterize a known or suspected lung cancer in
an area where community transmission of COVID-19
is present, we suggest that bronchoscopy be
performed in a timely and safe manner (Grade 2C).
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Remarks:
 Strategies to perform bronchoscopy in timely manner
should be developed locally, taking into account local
resource availability, including availability of personal
protective equipment, availability of COVID-19
testing, and availability of downstream resources
required for treatment (eg, surgery requires ICU beds
and ventilators).
 Regional availability of diagnostic and therapeutic
interventions for cancer patients should be consid-
ered. In particularly resource-depleted hospitals,
COVID-19 negative cancer patients should be
referred to other centers, preserving resources for
COVID-19 patients and facilitating safe, timely, and
effective care for the cancer patient as well.
 Although efforts should be made to provide timely
care, these should be balanced by the need to attend to
other dimensions of quality, including safety, effec-
tiveness, and consistency with patient values and
preferences.
The Institute of Medicine has identified timeliness
as one of the six dimensions of health-care quality.
For lung cancer, delays in care may lead to missed
opportunities for cure or palliation and emotional
distress. The CHEST Evidence-Based Guidelines and
the British Thoracic Society and the National
Cancer Network all address timeliness of care to
varying degrees, but they vary somewhat in the
details and definitions of what constitutes timely
care. Bronchoscopy is an integral part of lung
cancer care because it is often required for diagnosis
and staging, which in turn determines treatment.
Timeliness of bronchoscopic diagnosis impacts
everything that occurs downstream from it. Indeed,
guideline consistent care with bronchoscopic
endobronchial ultrasound for staging and diagnosis
as the first test in patients with T1-3, N1-3, M0
disease has been shown to decreases complications,
decrease number of tests required, and decrease time
to treatment.54
However, in the context of the COVID-19 epidemic,
there is a compelling need to consider the efficient
allocation of constrained resources. Balancing the need
to deliver high-quality cancer care and the public health
and resource allocation needs associated with the
COVID-19 pandemic requires careful consideration of
where resources can be deployed for the most benefit. In
the context of the COVID-19 pandemic, the question is
whether it is reasonable to forego or delay bronchoscopy
of patients with known or suspected lung cancer, and if
so for how long?
The answer to this question is highly context dependent
and will of course vary depending on the presentation of
the patient. In addition, optimal diagnostic and staging
strategies are contingent on the benefits and harms of
the available treatments.55 The availability of different
TABLE 2 ] Urgency of Bronchoscopy Procedures
Emergent Bronchoscopy Urgent Bronchoscopy Nonurgent Bronchoscopy
Severe or moderate symptomatic tracheal or
bronchial stenosis
Lung mass suspicious of cancer Mild tracheal or bronchial stenosis
Symptomatic central airway obstruction
(endotracheal or endobronchial mass or
mucus plug)
Mediastinal or hilar adenopathy
suspicious of cancer
Clearance of mucus
Massive hemoptysis Whole lung lavage High suspicion of sarcoidosis with
no immediate need to start
therapy
Migrated stent Foreign object aspiration Chronic interstitial lung disease
Mild to moderate hemoptysis Detection of chronic infection
mycobacterial
Suspected pulmonary infection in
patients who are
immunocompromised
Bronchoscopic lung volume
reduction
Bronchial thermoplasty
Chronic cough
Tracheobronchomalacia
evaluation
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treatment modalities during the COVID-19 pandemic
also needs to be considered because some treatment
alternatives, such as lobectomy for cure, may consume
resources that are particularly scarce (eg, ventilators).
A complete quantitative analysis of every possible
scenario according to resources availability and stage of
disease is beyond the scope of this guideline. We instead
focus on a more general question: What is the impact of
delays in care on lung cancer survival? The goal is to
summarize the available evidence to arrive at a more
nuanced understanding of how timeliness of care
impacts lung cancer outcomes. This information can in
turn be used to inform decision-making at the local level
as to how best to allocate available health-care resources.
To summarize the evidence of the impact of timeliness
of care on lung cancer outcomes, we used the third
edition of the CHEST evidence-based lung cancer
guidelines.56 A supplemental literature review identified
13 additional references.6-18 The methodology of the
studies, the definitions used, and the evidence quality
precluded arriving at a point estimate of the effect of
time delay on outcomes. Issues included varying
definitions of when cancer was first identified (eg,
symptoms vs imaging vs tissue diagnosis), which
interval was relevant (eg, symptoms to treatment
vs diagnosis to treatment), heterogeneity in populations
(eg, surgically treated vs all patients with lung cancer),
differences in histology (eg, all types vs non-small cell
lung cancer), intractable problems because of residual
confounding within groups, confounding by indication
(eg, sicker patients seen more rapidly), selection bias,
and failure to adjust for lead time bias (eg, measuring
survival from time of treatment rather than time of
presentation). We therefore have provided evidence
tables with the new studies identified, with additional
methodology comments (e-Appendix 2, 3).6-18,57-61
The available evidence is often conflicting regarding the
relationship between timeliness of care and
outcome.7,13,17 Paradoxically, multiple studies reported
that more timely care was associated with worse
outcomes.6,7,9,12,13 Two studies found evidence that the
impact of timeliness of care on survival varies based on
lung cancer stage.6,8 Timely care was associated with
improved survival in local and stage II disease.
Conversely, in patients with metastatic disease, timely
care was associated with decreased survival. These
findings explain the paradoxical and contradictory
results of earlier studies. In early stage disease, medical
emergencies are less common, and there is likely to be
less confounding by indication. In late stage disease,
confounding by indication plays a role (e-Appendix 2).
On balance, the available data suggest that although we
cannot precisely quantify the impact of delays in care, it
is probable that delays have a greater impact early in the
disease process.6,12,17 More timely care is likely to have
the greatest benefit in patients with stage IA2, IA3, IB,
IIA, and IIB disease.
When resources for cancer care are constrained because
of COVID-19, the first step is to take an inventory of
what treatments and diagnostic modalities are available
for cancer care. In hospitals most burdened by COVID-
19, surgery will not be an option; therefore,
collaboration with outside centers and referral may be
best. Inventory should not be just at the local hospital
level, but rather hospitals should share information
regarding availability of resources regionally, such as
ICU beds, ventilators, and types of services still available
for cancer care. If there is no availability because of the
absence of resources at one hospital, then referral to
outside centers is warranted. In areas with the highest
rates of COVID-19, referral of COVID-19-negative
patients with cancer to other centers will be a good
strategy. This requires coordination between centers,
hence the emphasis on taking inventory at both the
hospital and regional level. Cancer centers that are
physically separate from general hospitals with separate
teams would be able to serve this purpose well. This has
some appeal because it would keep vulnerable patients
with cancer out of hospitals with a high rate of COVID-
19, freeing up resources for patients with COVID-19. It
would also create a sort of reverse quarantine, where
care for COVID-19-negative patients with cancer would
be delivered.
Finally, although there is limited evidence of the benefit
of timeliness of care, there is evidence that guideline
consistent care leads to better outcomes.13,54,62 In a
study of 1,924 elderly patients, Nadpara et al13 found no
association between survival outcomes and timeliness of
care but did find an association with guideline consistent
care. Hence, the emphasis should still be on appropriate
evidence-based guideline consistent care. Regional
information sharing and collaboration between centers
with appropriate referral to optimize resource utilization
is probably the single most important intervention that
can help minimize delays in cancer care while
optimizing resource allocation. This will help to protect
COVID-19-negative patients with cancer from
becoming infected and will maximize resources for
patients with COVID-19.
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6. In patients with confirmed COVID-19 infection
who recover and need a routine bronchoscopy, we
suggest the timing of the procedure is customized
based on the indication for the procedure, the severity
of the COVID-19 infection and time from symptom
resolution (Ungraded Consensus-Based Statement).
Remarks: The exact time to perform bronchoscopy is
still unknown. It would be reasonable to wait at least
30 days from resolution of symptoms with negative
SARS-CoV-2 RNA tests from at least two consecutive
nasopharyngeal swab specimens collected $24 hours
apart. Further research is needed to better understand
optimal timing of bronchoscopy performance relative to
symptom resolution.
Patients who have confirmed COVID-19 infection
continue to shed the virus from the respiratory tract for
a variable period of time after resolution of
symptoms.63-67 We sought to determine the period of
time after which patients who have recovered from a
confirmed COVID-19 infection are no longer
considered contagious and routine bronchoscopy can be
performed safely without exposing HCWs to the risk of
contracting the infection.
Our systematic review did not identify any study
addressing time to performance of procedures in the
setting of SARS-CoV-2 infection. Viral shedding in
patients with COVID-19 infection varies depending on
disease severity. Patients who had mild illness tend to
shed the virus from the respiratory tract for a shorter
period compared with those with more severe disease.
Additionally, patients with mild disease tend to have an
earlier viral clearance than those with severe disease. In
one study, rRT-PCR test was negative in 90% of patients
with mild disease by day 10 from onset of symptoms,
whereas severe cases tested positive beyond day 10.63 In
another study, viral RNA was detected > 20 days from
onset of symptoms.64
Other studies on patients with COVID-19 infections
noted that rRT-PCR was positive from the respiratory
tract up to 37 days from onset of symptoms and for an
even longer duration in stool samples than throat
swabs.65,66 In a study comparing sputum samples with
pharyngeal swabs, sputum rRT-PCR reported positive
up to 39 days after pharyngeal swabs turned negative in
patients with COVID-19; the duration was longer in
patients who received steroids.67
Complicating the extended viral shedding is the
performance of the rRT-PCR test because it has been
shown to be false negative both in the early part of the
infection and after resolution of symptoms when viral
shedding may be below the threshold of detection for the
test.41
The CDC68 has guidance on discontinuation of
transmission-based precautions using both a test-based
and a non-test-based strategy. This guidance does not
extend to procedure timing, but it does favor a test-
based strategy in patients with severe illness,
immunocompromised state, and those being transferred
to long-term or assisted living facilities.
This panel reached a consensus that the timing of
nonurgent bronchoscopy in patients who have recovered
from COVID-19 infection will need to be individualized
based on disease severity, duration of illness, and a
negative SARS-CoV-2 RNA test from at least two
consecutive nasopharyngeal swab specimens collected $
24 h apart (total of two negative specimens). The exact
time to perform bronchoscopy is still unknown, but it
would be reasonable to wait at least 30 days from
resolution of symptoms. Further research is needed to
validate this suggested waiting period.
Discussion and Summary
The recommendation and suggestions outlined in this
document were specifically created to address what were
thought to be clinically common and urgent questions
that frontline physicians are likely to face. We focused
mainly on questions related to bronchoscopy as an AGP,
but it is important to note that the primary mode of
transmission for COVID-19 infection is droplets.
Therefore, contact precautions (face shield, mask, gown,
and gloves) are the integral components of PPE strategy
to prevent the transmission of this disease, and N-95
respirators or PAPRs represent additional precautions
during AGPs such as bronchoscopy.
We would like to stress that these protective strategies
can be rendered completely ineffective if proper training
on donning and doffing is not provided to HCWs.
Proper personnel instruction and practice for wearing
PPE should receive as much attention by health facilities
as the chosen strategy for protection.
There are three important limitations that need to be
kept in mind. The first is the overall paucity of robust
and direct evidence to inform the guidance. Although
this is not entirely surprising for a disease process that is
brand new to humanity, it underscores the importance
of multiinstitutional and multinational collaboration in
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collating and rapidly disseminating clinical experiences
and outcomes data under these unique circumstances.
Specialty societies can play an enormously helpful role in
such efforts and may be able to leverage their various
networks for this, and future, novel pandemics. Second,
because of the urgency of the situation, there may
have been important questions that were unavoidably
omitted in this particular statement. Information needs
to be available at the speed of relevance and
sometimes this results in a less comprehensive package.
Finally, although all direct and indirect evidence was
discussed with all panelists, literature search for every
PICO question was performed by one panelist
without an independent parallel search by a second
panel member. This was unavoidable because of the
limited time allotted for this effort and the desire to
rapidly disseminate useful information to frontline
physicians.
The strengths of this document are the multidisciplinary
panel that was composed of experienced
bronchoscopists and interventional pulmonologists,
infectious disease specialists, intensivists, respiratory
therapists, and trainees and the robust methodology to
formulate specific questions, evaluate the literature with
validated tools, and seek consensus while minimizing
groupthink.
Physicians searching for evidence on bronchoscopy
during this challenging time of the COVID-19 pandemic
should use this document as general guidance and adapt
it to their local situation. This statement should be
envisioned as a living document that should be updated
in the future as new evidence undoubtedly comes to
light.
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